

Supporting Information

**Efficiently enantioselective synthesis of pyrazolines and isoxazolines enabled
by iridium-catalyzed intramolecular allylic substitution reaction**

Fang Hu, Hua Zhang, Yun-Peng Chu, and Xin-Ping Hui*

*State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering,
Lanzhou University, Lanzhou 730000, P. R. China*

E-mail: huixp@lzu.edu.cn

Contents


1. General information.....	2
2. General procedure for synthesis of substrates 1a–1s and 3a–3p	2
3. General procedure for enantioselective synthesis of 1 <i>H</i> -pyrazolines 2a–2q , tetrahydro- pyridazine 2r and 1 <i>H</i> -1,2-diazepine 2s enabled by iridium-catalyzed intramolecular allylic substitution reaction.....	4
4. General procedure for enantioselective synthesis of dihydroisoxazoles 4a–4n , dihydro-4 <i>H</i> - 1,2-oxazine 4o , tetrahydro-1,2-oxazepine 4p enabled by iridium-catalyzed intramolecular allylic substitution reaction.....	12
5. Synthetic transformation of products.....	18
6. Scale-up synthesis of compound 2a	21
7. References.....	22
8. NMR spectra of compounds 2a–2s , 4a–4p and 5–8	23
9. HPLC spectra of compounds 2a–2s , 4a–4p and 5–6	63

1. General information


^1H NMR and ^{13}C NMR spectra were recorded on a Bruker AVANCE III 400 spectrometer using tetramethylsilane as internal reference, and chemical shifts (δ) and coupling constants (J) were expressed in ppm and Hz, respectively. Optical rotation was measured by the Perkin Elmer 341 polarimeter. The HRMS analysis was obtained on a Bruker Apex II FT-ICR mass spectrometer with ESI ionization method. The *ee* value determination was carried out using HPLC with chiral Chirapak column on Agilent 1260 with a UV-detector. Melting points were taken on an XT-4 melting point apparatus and were uncorrected. Dichloromethane and acetonitrile were freshly distilled from phosphorous pentoxide. Toluene and THF were freshly distilled from a deep-blue solution of sodium-benzophenone under argon. Phosphoramidite ligand **L1-L2**, $[\text{Ir}(\text{COD})\text{Cl}]_2$ and *n*-propylamine were purchased from commercial suppliers and used directly. All syntheses and manipulations were carried out under a dry argon atmosphere. Flash column chromatography was carried out utilizing 200–300 mesh silica gel.

2. General procedure for synthesis of substrates 1a–1s and 3a–3p


2.1 General procedure for synthesis of β,γ -allyl carbonate hydrazones 1a–1r



To a solution of aldehyde (20.0 mmol) in THF (30 mL) was added 3-bromoprop-1-ene (40.0 mmol, 3.46 mL, 2.0 equiv.) and saturated aqueous NH_4Cl (30 mL). Then, zinc dust (40.0 mmol, 2.6 g, 2.0 equiv.) was slowly added to the solution at 0 °C and the resulting suspension was stirred overnight at room temperature. Upon completion of the reaction (monitored by TLC), the reaction mixture was filtered and extracted with ethyl acetate (20 mL \times 3). The combined organic extracts were washed with brine, dried over Na_2SO_4 , filtered, and concentrated in reduced pressure. The 1-substituted but-3-en-1-ol **S1** was directly used in next step without further purification.^[1]



Under argon atmosphere, 1-substituted but-3-en-1-ol **S1** (8.0 mmol) and (*Z*)-but-2-ene-1,4-diyl diethyl dicarbonate (12 mmol, 2.79 g, 1.5 equiv.) were dissolved in anhydrous CH_2Cl_2 (20 mL) at room temperature. The solution of Grubbs catalyst 2nd generation (0.16 mmol, 136 mg, 2 mol %) in anhydrous CH_2Cl_2 (5 mL) was added and the mixture was refluxed overnight. The solvent was removed under reduced pressure and the residue was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate = 9/1) to afford product **S2** in 40–65% yields.^[2]




Compound **S2** (5 mmol) was dissolved in diethyl ether at 0 °C and Jones reagent (10 mmol, 4.0 mL, 2.5 M, 2 equiv.) was added dropwise at 0 °C. Then, the mixture was warmed to room temperature and stirred for another 2.5 h. After completion of the reaction (monitored by TLC), the ether layer was separated and the aqueous layer was extracted with ethyl acetate (20 mL×3). The combined organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated in reduced pressure. The crude product was directly used in next step without further purification.^[1]

To a solution of β,γ -unsaturated ketone (4 mmol) in MeOH (16 mL), *p*-toluenesulfonyl hydrazide (4.8 mmol, 0.894 g, 1.2 equiv.) was added at 0 °C. The mixture was stirred at 0 °C until the reaction was completed (monitored by TLC). The solvent was removed under reduced pressure, and the residue was purified by flash column chromatography on silica gel to afford compounds **1a–1o** in 24–43% yield.


The substrates **1p**, **1r** and **1s** were synthesized using the similar methods.

2.2 General procedure for synthesis of β,γ -allyl carbonate oximes **3a–3p**



1-Aryl-but-3-en-1-ol **S1** (20 mmol) was dissolved in diethyl ether at 0 °C and Jones reagent (40 mmol, 16.0 mL, 2.5 M, 2 equiv.) was added dropwise at 0 °C. The resulting mixture was warmed to room temperature and stirred for another 4 h. After completion of the reaction (monitored by TLC), the ether layer was separated and the aqueous layer was extracted with ethyl acetate (20 mL×3). The combined organic phase was washed with water and brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude β,γ -unsaturated ketone was directly used in next step without further purification.^[1]


To a solution of hydroxylamine hydrochloride (50 mmol, 3.48 g, 5 equiv.) and sodium acetate (70 mmol, 5.74g, 7 equiv.) in ethanol (50 mL) was added β,γ -unsaturated ketone (10 mmol) in ethanol (8 mL). The reaction mixture was stirred overnight at room temperature and concentrated under reduced pressure. Then, the mixture was extracted with ethyl acetate (30 mL×3) and the combined organic phase was washed with water and brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (petroleum ether/ethyl acetate = 9/1) to afford β,γ -unsaturated oxime **S3** in 50–70% yield.^[3]



Under argon atmosphere, β,γ -unsaturated oxime **S3** (4.0 mmol) and (*Z*)-but-2-ene-1,4-diyl diethyl dicarbonate (6 mmol, 1.40 g, 1.5 equiv.) were dissolved in dry CH_2Cl_2 (10 mL). To the solution was added the solution of Grubbs catalyst 2nd generation (0.08 mmol, 68 mg, 2 mol %) in dry CH_2Cl_2 (3 mL). The mixture was refluxed overnight and the solvent was removed under reduced pressure. The crude product was purified by flash column chromatography on silica gel (petroleum ether/ethyl acetate = 9/1) to afford the products **3a–3n** in 20–45% yield.


The substrates **3o–3p** were synthesized using the similar methods.

3. General procedure for enantioselective synthesis of 1*H*-pyrazolines **2a–2q**, tetrahydropyridazine **2r** and 1*H*-1,2-diazepine **2s** enabled by iridium-catalyzed intramolecular allylic substitution reactions




A flame dried Schlenk tube was cooled to room temperature and filled with argon. To this flask were added $[\text{Ir}(\text{COD})\text{Cl}]_2$ (0.004 mmol, 4 mol %), phosphoramidite ligand **L2** (0.008 mmol, 8 mol %), *n*-propylamine (0.5 mL) and THF (0.5 mL). The reaction mixture was heated at 50 °C for 0.5 h and the volatile solvent was removed *in vacuo* to afford a pale-yellow solid. Then, K_2CO_3 (0.05 mmol, 0.5 equiv.) and a solution substrate **1** (0.1 mmol) in CH_2Cl_2 (2 mL) were added. The reaction mixture was stirred for another 20 h. Upon completion of the reaction (monitored by TLC), the reaction mixture was filtrated with celite and washed with CH_2Cl_2 . The solvent was removed under reduced pressure and the residue was purified by flash column chromatography on silica gel to afford the product **2**.

(*R*)-3-phenyl-1-tosyl-5-vinyl-4,5-dihydro-1*H*-pyrazole (**2a**)




white solid, mp 107.2 – 107.8 °C, 32.0 mg, 98% yield, $[\alpha]_D^{26} +24.6$ (c 0.57, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 8.4 Hz, 2H), 7.65 (dd, J = 7.6, 2.4 Hz, 2H), 7.40 – 7.35 (m, 3H), 7.28 (d, J = 8.0 Hz, 2H), 6.12 – 6.03 (m, 1H), 5.36 (d, J = 17.2 Hz, 1H), 5.29 (d, J = 10.0 Hz, 1H), 4.35 – 4.28 (m, 1H), 3.21 (dd, J = 16.8, 10.8 Hz, 1H), 2.96 (dd, J = 17.2, 10.0 Hz, 1H), 2.39 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 157.04, 144.21, 136.45, 132.46, 130.79, 130.56, 129.50, 128.76, 128.62, 126.85, 117.73, 64.63, 40.22, 21.59. HRMS (ESI): Exact Mass Calcd. for C₁₈H₁₉N₂O₂S (M+H)⁺: 327.1162, Found: 327.1165. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: t_{major} = 26.642 min, t_{minor} = 33.923 min, 96% ee).

(R)-3-(4-fluorophenyl)-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2b)




white solid, mp 161.7 – 162.9 °C, 32.0 mg, 93% yield, $[\alpha]_D^{26} +20.0$ (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, J = 8.4 Hz, 2H), 7.62 (dd, J = 8.8, 5.6 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 7.04 (t, J = 8.4 Hz, 2H), 6.09 – 6.01 (m, 1H), 5.35 (d, J = 16.8 Hz, 1H), 5.27 (d, J = 10.4 Hz, 1H), 4.34 – 4.27 (m, 1H), 3.18 (dd, J = 16.8, 10.8 Hz, 1H), 2.92 (dd, J = 16.8, 10.0 Hz, 1H), 2.37 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 165.35, 162.85, 156.06, 144.30, 136.31, 132.39, 128.90, 128.82, 128.73, 127.08, 127.05, 117.84, 115.92, 115.70, 64.69, 40.26, 21.61. HRMS (ESI): Exact Mass Calcd. for C₁₈H₁₈FN₂O₂S (M+H)⁺: 345.1068, Found: 345.1072. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: t_{major} = 23.365 min, t_{minor} = 29.963 min, 97% ee).

(R)-3-(4-chlorophenyl)-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2c)




colorless oil, 32.5 mg, 90% yield, $[\alpha]_D^{26} -10.0$ (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, J = 8.4 Hz, 2H), 7.58 (dd, J = 6.8, 2.0 Hz, 2H), 7.35 – 7.33 (m, 2H), 7.29 (d, J = 8.4 Hz, 2H), 6.11 – 6.02 (m, 1H), 5.37 (d, J = 17.2 Hz, 1H), 5.29 (d, J = 10.4 Hz, 1H), 4.37 – 4.30 (m, 1H), 3.19 (dd, J = 16.8, 10.8 Hz, 1H), 2.93 (dd, J = 16.8, 10.0 Hz, 1H), 2.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 155.89, 144.29, 136.58, 136.19, 132.38, 129.49, 129.23, 128.88, 128.67, 128.01, 117.87, 64.71, 40.05, 21.56. HRMS (ESI): Exact Mass Calcd. for C₁₈H₁₈ClN₂O₂S (M+H)⁺: 361.0772, Found: 361.0777. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: t_{major} = 27.728 min, t_{minor} = 33.757 min, 93% ee).

(R)-3-(4-bromophenyl)-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2d)




white solid, mp 149.8 – 150.9 °C, 34.8 mg, 86% yield, $[\alpha]_D^{26}$ –55.0 (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, J = 8.4 Hz, 2H), 7.49 (s, 4H), 7.28 (d, J = 8.0 Hz, 2H), 6.10 – 6.01 (m, 1H), 5.35 (d, J = 17.2 Hz, 1H), 5.28 (d, J = 10.0 Hz, 1H), 4.36 – 4.29 (m, 1H), 3.18 (dd, J = 17.2, 10.8 Hz, 1H), 2.92 (dd, J = 16.8, 10.0 Hz, 1H), 2.38 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 156.01, 144.35, 136.22, 132.41, 131.89, 129.70, 129.54, 128.71, 128.25, 125.00, 117.94, 64.78, 40.04, 21.62. HRMS (ESI): Exact Mass Calcd. for C₁₈H₁₈BrN₂O₂S (M+H)⁺: 405.0267, Found: 405.0272. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 0.5 mL/min, retention time: t_{major} = 28.883 min, t_{minor} = 33.922 min, 90% ee).

(R)-3-(*p*-tolyl)-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2e)



colorless oil, 31.3 mg, 92% yield, $[\alpha]_D^{26}$ –33.0 (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 8.4 Hz, 2H), 6.10 – 6.01 (m, 1H), 5.34 (d, J = 17.2 Hz, 1H), 5.26 (d, J = 10.0 Hz, 1H), 4.29 – 4.22 (m, 1H), 3.17 (dd, J = 16.8, 10.4 Hz, 1H), 2.92 (dd, J = 16.8, 10.0 Hz, 1H), 2.36 (s, 3H), 2.34 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 157.22, 144.16, 140.99, 136.54, 132.33, 129.48, 129.33, 128.76, 128.00, 126.83, 117.64, 64.55, 40.26, 21.59, 21.48. HRMS (ESI): Exact Mass Calcd. for C₁₉H₂₁N₂O₂S (M+H)⁺: 341.1318, Found: 341.1323. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: t_{major} = 30.452 min, t_{minor} = 35.454 min, 97% ee).


(R)-3-(4-methoxyphenyl)-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2f)



white solid, mp 147.1 – 148.6 °C, 19.9 mg, 56% yield, $[\alpha]_D^{26}$ –56.0 (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 8.0 Hz, 2H), 7.60 (d, J = 8.8 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 6.88 (d, J = 9.2 Hz,


2H), 6.12 – 6.04 (m, 1H), 5.36 (d, $J = 17.2$ Hz, 1H), 5.28 (d, $J = 10.0$ Hz, 1H), 4.30 – 4.23 (m, 1H), 3.83 (s, 3H), 3.17 (dd, $J = 16.8, 10.8$ Hz, 1H), 2.93 (dd, $J = 16.8, 10.0$ Hz, 1H), 2.39 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 161.52, 156.88, 144.11, 136.60, 132.36, 129.45, 128.79, 128.49, 123.41, 117.58, 114.03, 64.48, 55.39, 40.31, 21.59. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_3\text{S}$ ($\text{M}+\text{H}$) $^+$: 357.1267, Found: 357.1274. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 46.998$ min, $t_{\text{minor}} = 66.760$ min, 98% ee).

(*R*)-3-(1,1'-biphenyl)-1-tosyl-5-vinyl-4,5-dihydro-1*H*-pyrazole (2g)




white solid, mp 158.6 – 159.4 °C, 35.4 mg, 88% yield, $[\alpha]_{\text{D}}^{26} -111.0$ (c 1.0, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.83 (d, $J = 8.0$ Hz, 2H), 7.72 (d, $J = 8.4$ Hz, 2H), 7.61 – 7.58 (m, 4H), 7.47 – 7.43 (m, 2H), 7.39 – 7.35 (m, 1H), 7.30 (d, $J = 8.0$ Hz, 2H), 6.14 – 6.05 (m, 1H), 5.38 (d, $J = 17.2$ Hz, 1H), 5.30 (d, $J = 10.0$ Hz, 1H), 4.37 – 4.29 (m, 1H), 3.25 (dd, $J = 16.8, 10.8$ Hz, 1H), 2.99 (dd, $J = 16.8, 10.0$ Hz, 1H), 2.39 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 156.76, 144.22, 143.30, 140.03, 136.46, 132.46, 129.65, 129.52, 128.93, 128.77, 127.94, 127.33, 127.26, 127.05, 117.76, 64.68, 40.23, 21.61. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{24}\text{H}_{23}\text{N}_2\text{O}_2\text{S}$ ($\text{M}+\text{H}$) $^+$: 403.1475, Found: 403.1480. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 49.871$ min, $t_{\text{minor}} = 59.985$ min, 95% ee).

(*R*)-3-(*m*-tolyl)-1-tosyl-5-vinyl-4,5-dihydro-1*H*-pyrazole (2h)




white solid, mp 163.5 – 164.8 °C, 32.0 mg, 94% yield, $[\alpha]_{\text{D}}^{26} -26.0$ (c 1.0, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.81 (d, $J = 8.4$ Hz, 2H), 7.51 (s, 1H), 7.42 (d, $J = 7.6$ Hz, 1H), 7.30 – 7.20 (m, 4H), 6.12 – 6.03 (m, 1H), 5.36 (d, $J = 16.8$ Hz, 1H), 5.28 (d, $J = 10.4$ Hz, 1H), 4.33 – 4.26 (m, 1H), 3.20 (dd, $J = 16.8, 10.8$ Hz, 1H), 2.95 (dd, $J = 16.8, 10.0$ Hz, 1H), 2.39 (s, 3H), 2.36 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.25, 144.17, 138.40, 136.51, 132.44, 131.40, 130.69, 129.49, 128.74, 128.50, 127.39, 124.07, 117.64, 64.53, 40.28, 21.58, 21.31. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2\text{S}$ ($\text{M}+\text{H}$) $^+$: 341.1318, Found: 341.1325. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 21.884$ min, $t_{\text{minor}} = 28.315$ min, 97% ee).

(R)-1-tosyl-3-(trifluoromethyl)-5-vinyl-4,5-dihydro-1H-pyrazole (2i)




colorless oil, 38.2 mg, 97% yield, $[\alpha]_D^{26} +17.0$ (c 1.0, CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.86 – 7.79 (m, 4H), 7.64 (d, $J = 7.6$ Hz, 1H), 7.51 (t, $J = 7.6$ Hz, 1H), 7.30 (d, $J = 8.0$ Hz, 2H), 6.11 – 6.02 (m, 1H), 5.38 (d, $J = 17.2$ Hz, 1H), 5.30 (d, $J = 10.4$ Hz, 1H), 4.41 – 4.34 (m, 1H), 3.26 (dd, $J = 16.8, 10.8$ Hz, 1H), 2.98 (dd, $J = 16.8, 10.0$ Hz, 1H), 2.39 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 155.63, 144.49, 136.07, 132.37, 131.64, 131.37, 131.05, 129.88, 129.61, 129.26, 128.68, 127.01, 126.98, 125.06, 123.56, 123.52, 122.35, 118.08, 64.87, 40.04, 21.60. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{19}\text{H}_{18}\text{F}_3\text{N}_2\text{O}_2\text{S}$ ($\text{M}+\text{H}$) $^+$: 395.1036, Found: 395.1041. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 92/8, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 38.514$ min, $t_{\text{minor}} = 41.838$ min, 95% ee).

(R)-3-(3-chlorophenyl)-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2j)



colorless oil, 34.2 mg, 95% yield, $[\alpha]_D^{26} -7.0$ (c 1.0, CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.81 (d, $J = 8.4$ Hz, 2H), 7.64 (s, 1H), 7.51 (d, $J = 7.6$ Hz, 1H), 7.37 (d, $J = 8.0$ Hz, 1H), 7.33 – 7.30 (m, 3H), 6.11 – 6.02 (m, 1H), 5.37 (d, $J = 17.2$ Hz, 1H), 5.30 (d, $J = 10.4$ Hz, 1H), 4.38 – 4.31 (m, 1H), 3.21 (dd, $J = 16.8, 10.8$ Hz, 1H), 2.94 (dd, $J = 16.8, 10.0$ Hz, 1H), 2.41 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 155.72, 144.40, 136.16, 134.77, 132.54, 132.42, 130.49, 129.92, 129.59, 128.70, 126.78, 124.90, 117.98, 64.75, 40.06, 21.62. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{18}\text{H}_{18}\text{ClN}_2\text{O}_2\text{S}$ ($\text{M}+\text{H}$) $^+$: 361.0772, Found: 361.0776. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 19.910$ min, $t_{\text{minor}} = 24.079$ min, 97% ee).


(R)-3-(2-chlorophenyl)-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2k)



colorless oil, 18.4 mg, 51% yield, $[\alpha]_D^{26} +83.0$ (c 1.0, CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.73 (d, $J = 8.4$ Hz, 2H), 7.50 (dd, $J = 7.6, 2.0$ Hz, 1H), 7.27 – 7.14 (m, 5H), 6.03 – 5.95 (m, 1H), 5.25 (d, $J = 17.2$ Hz,


1H), 5.19 (d, $J = 10.4$ Hz, 1H), 4.25 – 4.18 (m, 1H), 3.24 (dd, $J = 17.2, 10.4$ Hz, 1H), 3.07 (dd, $J = 17.2, 10.4$ Hz, 1H), 2.33 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.21, 144.37, 136.08, 132.80, 132.39, 131.08, 130.55, 130.54, 130.26, 129.51, 128.85, 126.91, 117.97, 65.48, 43.17, 21.63. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{18}\text{H}_{18}\text{ClN}_2\text{O}_2\text{S}$ ($\text{M}+\text{H}$) $^+$: 361.0772, Found: 361.0778. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: $t_{\text{minor}} = 21.507$ min, $t_{\text{major}} = 26.629$ min, 89% ee).

(R)-3-(naphthalen-2-yl)-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2l)




white solid, mp 124.6 – 125.3 °C, 35.3 mg, 94% yield, $[\alpha]_{\text{D}}^{26} +5.0$ (c 1.0, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.98 (dd, $J = 8.8, 1.6$ Hz, 1H), 7.85 – 7.80 (m, 6H), 7.54 – 7.47 (m, 2H), 7.28 (d, $J = 8.0$ Hz, 2H), 6.16 – 6.07 (m, 1H), 5.40 (d, $J = 17.2$ Hz, 1H), 5.31 (d, $J = 10.4$ Hz, 1H), 4.40 – 4.33 (m, 1H), 3.34 (dd, $J = 16.8, 10.8$ Hz, 1H), 3.07 (dd, $J = 16.8, 10.0$ Hz, 1H), 2.37 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.15, 144.25, 136.48, 134.25, 132.82, 132.43, 129.52, 128.77, 128.46, 128.45, 128.38, 127.84, 127.40, 127.34, 126.76, 123.53, 117.78, 64.76, 40.18, 21.59. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{O}_2\text{S}$ ($\text{M}+\text{H}$) $^+$: 377.1318, Found: 377.1322. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 33.806$ min, $t_{\text{minor}} = 40.933$ min, 99% ee).

(R)-tert-butyl-3-(1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazol-3-yl)-1H-indole-1-carboxylate (2m)




colorless oil, 46.0 mg, 99% yield, $[\alpha]_{\text{D}}^{27} -37.0$ (c 1.0, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 8.38 – 8.36 (m, 1H), 8.12 (d, $J = 7.6$ Hz, 1H), 7.85 (d, $J = 8.4$ Hz, 2H), 7.66 (s, 1H), 7.43 – 7.36 (m, 2H), 7.26 (d, $J = 8.4$ Hz, 2H), 6.15 – 6.06 (m, 1H), 5.40 (d, $J = 17.2$ Hz, 1H), 5.31 (d, $J = 10.0$ Hz, 1H), 4.32 – 4.25 (m, 1H), 3.23 (dd, $J = 16.4, 10.4$ Hz, 1H), 3.01 (dd, $J = 16.8, 10.0$ Hz, 1H), 2.36 (s, 3H), 1.67 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 152.80, 149.17, 144.16, 136.48, 135.68, 132.26, 129.44, 128.76, 127.50, 127.08, 125.57, 123.98, 123.04, 117.75, 115.01, 113.27, 84.86, 63.67, 41.02, 28.13, 21.57. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{25}\text{H}_{28}\text{N}_3\text{O}_4\text{S}$ ($\text{M}+\text{H}$) $^+$: 466.1795, Found: 466.1798. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: $t_{\text{minor}} = 23.247$ min, $t_{\text{major}} = 29.962$ min, 97% ee).

(R)-3-(furan-2-yl)-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2n)




colorless oil, 25.9 mg, 82% yield, $[\alpha]_D^{27} +70.0$ (c 0.5, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.81 (d, $J = 8.0$ Hz, 2H), 7.49 (d, $J = 1.2$ Hz, 1H), 7.30 (d, $J = 8.0$ Hz, 2H), 6.78 (d, $J = 3.2$ Hz, 1H), 6.47 (dd, $J = 3.6$, 2.0 Hz, 1H), 6.09 – 6.01 (m, 1H), 5.36 (d, $J = 17.2$ Hz, 1H), 5.29 (d, $J = 10.4$ Hz, 1H), 4.32 – 4.25 (m, 1H), 3.18 (dd, $J = 16.8$, 10.8 Hz, 1H), 2.93 (dd, $J = 17.2$, 10.0 Hz, 1H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 148.85, 146.41, 144.68, 144.25, 136.12, 132.38, 129.53, 128.79, 117.89, 112.44, 111.97, 64.08, 40.07, 21.62. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_3\text{S}$ ($\text{M}+\text{H}$) $^+$: 317.0954, Found: 317.0960. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 60/40, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 20.299$ min, $t_{\text{minor}} = 45.552$ min, 94% ee).

(R)-3-(thiophen-2-yl)-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2o)



white solid, mp 145.1 – 146.9 °C, 32.2 mg, 97% yield, $[\alpha]_D^{27} -65.0$ (c 1.0, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, $J = 8.4$ Hz, 2H), 7.41 (dd, $J = 5.2$, 0.8 Hz, 1H), 7.29 (d, $J = 8.0$ Hz, 2H), 7.15 (dd, $J = 3.6$, 0.8 Hz, 1H), 7.02 (dd, $J = 4.8$, 3.6 Hz, 1H), 6.11 – 6.02 (m, 1H), 5.36 (d, $J = 17.2$ Hz, 1H), 5.29 (d, $J = 10.4$ Hz, 1H), 4.33 – 4.26 (m, 1H), 3.19 (dd, $J = 16.8$, 10.8 Hz, 1H), 2.97 (dd, $J = 16.8$, 10.0 Hz, 1H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 152.69, 144.25, 136.23, 134.33, 132.25, 129.49, 129.32, 128.93, 128.84, 127.44, 117.85, 64.70, 40.93, 21.60. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_2\text{S}_2$ ($\text{M}+\text{H}$) $^+$: 333.0726, Found: 333.0732. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 29.916$ min, $t_{\text{minor}} = 35.600$ min, 98% ee).


(R)-5-methyl-3-phenyl-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2p)



white solid, mp 120.1 – 120.8 °C, 31.9 mg, 94% yield, $[\alpha]_D^{27} +19.0$ (c 1.0, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.90 (d, $J = 8.4$ Hz, 2H), 7.67 – 7.65 (m, 2H), 7.39 – 7.37 (m, 3H), 7.27 (d, $J = 7.2$ Hz, 2H), 6.04 (dd, $J = 17.2$, 10.8 Hz, 1H), 5.28 (d, $J = 17.6$ Hz, 1H), 5.15 (d, $J = 10.8$ Hz, 1H), 3.21 (d, $J = 16.4$ Hz, 1H),


3.05 (d, $J = 16.8$ Hz, 1H), 2.39 (s, 3H), 1.69 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 153.45, 143.50, 139.66, 137.03, 131.23, 130.17, 129.14, 128.59, 128.37, 126.53, 114.76, 71.49, 47.98, 23.65, 21.57. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2\text{S}$ ($\text{M}+\text{H}$) $^+$: 341.1318, Found: 341.1325. HPLC (Chiralpak AD-H column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 25.521$ min, $t_{\text{minor}} = 30.528$ min, 30% ee).

(R)-3-cyclohexyl-1-tosyl-5-vinyl-4,5-dihydro-1H-pyrazole (2q)




colorless oil, 30.6 mg, 92% yield, $[\alpha]_{\text{D}}^{26} +242.0$ (c 1.0, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, $J = 7.6$ Hz, 2H), 7.31 (d, $J = 7.6$ Hz, 2H), 6.03 – 5.95 (m, 1H), 5.28 (d, $J = 17.2$ Hz, 1H), 5.22 (d, $J = 10.0$ Hz, 1H), 4.09 – 4.03 (m, 1H), 2.73 – 2.66 (m, 1H), 2.57 – 2.50 (m, 1H), 2.43 (s, 3H), 2.28 (s, 1H), 1.71 – 1.68 (m, 5H), 1.24 – 1.17 (m, 5H). ^{13}C NMR (100 MHz, CDCl_3) δ 166.32, 144.04, 136.71, 131.96, 129.26, 128.87, 117.20, 63.75, 40.67, 39.22, 30.29, 29.91, 25.78, 25.64, 25.57, 21.61. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{18}\text{H}_{25}\text{N}_2\text{O}_2\text{S}$ ($\text{M}+\text{H}$) $^+$: 333.1631, Found: 333.1629. HPLC (Chiralpak AD-H column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, retention time: $t_{\text{minor}} = 12.270$ min, $t_{\text{major}} = 14.196$ min, 97% ee).

(R)-3-phenyl-1-tosyl-6-vinyl-1,4,5,6-tetrahydropyridazine (2r)




colorless oil, 30.9 mg, 91% yield, $[\alpha]_{\text{D}}^{27} +150.0$ (c 1.0, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3) δ 7.86 (d, $J = 8.4$ Hz, 2H), 7.69 (dd, $J = 7.6, 2.0$ Hz, 2H), 7.38 – 7.32 (m, 3H), 7.26 (d, $J = 8.0$ Hz, 2H), 5.66 – 5.57 (m, 1H), 5.19 – 5.18 (m, 1H), 5.14 – 5.11 (m, 1H), 5.03 – 5.00 (m, 1H), 2.63 – 2.57 (m, 1H), 2.41 – 2.31 (m, 4H), 2.06 – 2.00 (m, 1H), 1.98 – 1.90 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 147.45, 143.58, 136.95, 135.92, 134.30, 129.21, 129.14, 128.41, 128.32, 125.24, 117.77, 53.99, 23.27, 21.57, 18.55. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2\text{S}$ ($\text{M}+\text{H}$) $^+$: 341.1318, Found: 341.1326. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: $t_{\text{minor}} = 23.508$ min, $t_{\text{major}} = 27.270$ min, 96% ee).

(R)-3-phenyl-1-tosyl-7-vinyl-4,5,6,7-tetrahydro-1H-1,2-diazepine (2s)




white solid, mp 125.2 – 126.9 °C, 35.0 mg, 99% yield, $[\alpha]_D^{27} +678.0$ (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, $J = 8.4$ Hz, 2H), 7.72 (dd, $J = 8.0, 1.6$ Hz, 2H), 7.42 – 7.37 (m, 3H), 7.30 (d, $J = 8.0$ Hz, 2H), 5.28 – 5.20 (m, 1H), 5.07 – 5.06 (m, 1H), 4.90 (d, $J = 17.2$ Hz, 1H), 4.80 (d, $J = 10.8$ Hz, 1H), 3.08 – 3.03 (m, 1H), 2.92 – 2.85 (m, 1H), 2.42 (s, 3H), 2.10 – 2.05 (m, 2H), 1.76 – 1.68 (m, 1H), 1.51 – 1.40 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 168.71, 143.77, 137.29, 134.44, 133.64, 130.15, 129.41, 129.09, 128.41, 127.20, 117.13, 60.53, 33.96, 30.73, 21.63, 15.74. HRMS (ESI): Exact Mass Calcd. for C₂₀H₂₃N₂O₂S (M+H)⁺: 355.1475, Found: 355.1482. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, retention time: $t_{\text{minor}} = 15.596$ min, $t_{\text{major}} = 24.030$ min, 92% ee).

4. General procedure for enantioselective synthesis of dihydroisoxazoles 4a–4n, dihydro-4*H*-1,2-oxazine 4o, tetrahydro-1,2-oxazepine 4p enabled by iridium-catalyzed intramolecular allylic substitution reactions




A flame dried Schlenk tube was cooled to room temperature and filled with argon. To this flask were added [Ir(COD)Cl]₂ (0.004 mmol, 4 mol %), phosphoramidite ligand L₂ (0.008 mmol, 8 mol %), *n*-propylamine (0.5 mL) and THF (0.5 mL). The reaction mixture was heated at 50 °C for 0.5 h and the volatile solvents were removed *in vacuo* to afford a pale-yellow solid. Then, K₂CO₃ (0.05 mmol, 0.5 equiv.) and a solution of allylic carbonate **3** (0.1 mmol) in CH₂Cl₂ (2 mL) were added. The reaction mixture was stirred for another 20 h. Upon completion of the reaction (monitored by TLC), the reaction mixture was filtrated with celite and washed with CH₂Cl₂. The solvent was removed under reduced pressure and the residue was purified by flash column chromatography on silica gel to afford the product **4**.

(*R*)-3-phenyl-5-vinyl-4,5-dihydroisoxazole (4a)




white solid, mp 43.6 – 44.5 °C, 15.7 mg, 91% yield, $[\alpha]_D^{24}$ –110.0 (c 0.5, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.68 – 7.66 (m, 2H), 7.41 – 7.40 (m, 3H), 6.01 – 5.93 (m, 1H), 5.41 (d, J = 17.2 Hz, 1H), 5.27 (d, J = 10.0 Hz, 1H), 5.20 – 5.13 (m, 1H), 3.50 (dd, J = 16.4, 10.4 Hz, 1H), 3.13 (dd, J = 16.4, 8.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 156.36, 136.10, 130.08, 129.57, 128.71, 126.68, 117.93, 82.03, 40.53. HRMS (ESI): Exact Mass Calcd. for C₁₁H₁₂NO (M+H)⁺: 174.0913, Found: 174.0916. HPLC (Chiralpak IC column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: t_{major} = 28.121 min, t_{minor} = 30.563 min, 92% ee).

(R)-3-(4-fluorophenyl)-5-vinyl-4,5-dihydroisoxazole (4b)




white solid, mp 67.0 – 67.7 °C, 18.9 mg, 99% yield, $[\alpha]_D^{25}$ –119.0 (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (dd, J = 8.8, 5.6 Hz, 2H), 7.09 (t, J = 8.8 Hz, 2H), 6.00 – 5.92 (m, 1H), 5.41 (d, J = 16.8 Hz, 1H), 5.27 (d, J = 10.4 Hz, 1H), 5.19 – 5.13 (m, 1H), 3.48 (dd, J = 16.4, 10.8 Hz, 1H), 3.10 (dd, J = 16.4, 8.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 165.00, 162.51, 155.39, 135.97, 128.65, 128.56, 125.87, 125.84, 118.04, 115.97, 115.75, 82.14, 40.58. HRMS (ESI): Exact Mass Calcd. for C₁₁H₁₁FNO (M+H)⁺: 192.0819, Found: 192.0821. HPLC (Chiralpak IC column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: t_{major} = 19.721 min, t_{minor} = 22.818 min, 76% ee).

(R)-3-(4-chlorophenyl)-5-vinyl-4,5-dihydroisoxazole (4c)




white solid, mp 84.5 – 85.4 °C, 19.3 mg, 93% yield, $[\alpha]_D^{25}$ –130.0 (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.60 (dd, J = 6.8, 2.0 Hz, 2H), 7.37 (dd, J = 6.8, 2.0 Hz, 2H), 6.00 – 5.92 (m, 1H), 5.41 (d, J = 17.2 Hz, 1H), 5.28 (d, J = 10.4 Hz, 1H), 5.20 – 5.14 (m, 1H), 3.47 (dd, J = 16.4, 10.4 Hz, 1H), 3.09 (dd, J = 16.4, 8.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 155.45, 136.04, 135.87, 129.00, 128.09, 127.89, 118.13, 82.29, 40.35. HRMS (ESI): Exact Mass Calcd. for C₁₁H₁₁ClNO (M+H)⁺: 208.0524, Found: 208.0526. HPLC (Chiralpak IC column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: t_{major} = 20.322 min, t_{minor} = 22.814 min, 91% ee).

(R)-3-(4-bromophenyl)-5-vinyl-4,5-dihydroisoxazole (4d)




white solid, mp 100.1 – 101.2 °C, 22.9 mg, 91% yield, $[\alpha]_D^{22} -86.0$ (c 0.5, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.53 (s, 4H), 6.00 – 5.91 (m, 1H), 5.41 (d, $J = 16.8$ Hz, 1H), 5.28 (d, $J = 10.0$ Hz, 1H), 5.20 – 5.14 (m, 1H), 3.47 (dd, $J = 16.4, 10.4$ Hz, 1H), 3.09 (dd, $J = 16.4, 8.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 155.56, 135.85, 131.96, 128.52, 128.11, 124.35, 118.19, 82.34, 40.28. HRMS (ESI): Exact Mass Calcd. for C₁₁H₁₁BrNO (M+H)⁺: 252.0019, Found: 252.0022. HPLC (Chiralpak IC column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 22.617$ min, $t_{\text{minor}} = 25.395$ min, 93% ee).

(R)-3-(*p*-tolyl)-5-vinyl-4,5-dihydroisoxazole (4e)




white solid, mp 68.2 – 70.1 °C, 17.2 mg, 92% yield, $[\alpha]_D^{25} -171.0$ (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, $J = 8.4$ Hz, 2H), 7.21 (d, $J = 8.0$ Hz, 2H), 6.01 – 5.93 (m, 1H), 5.40 (d, $J = 16.8$ Hz, 1H), 5.26 (d, $J = 10.4$ Hz, 1H), 5.17 – 5.11 (m, 1H), 3.48 (dd, $J = 16.4, 10.4$ Hz, 1H), 3.11 (dd, $J = 16.4, 8.4$ Hz, 1H), 2.38 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 156.33, 140.31, 136.21, 129.41, 126.75, 126.63, 117.83, 81.87, 40.66, 21.43. HRMS (ESI): Exact Mass Calcd. for C₁₂H₁₄NO (M+H)⁺: 188.1070, Found: 188.1073. HPLC (Chiralpak AD–H column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 15.941$ min, $t_{\text{minor}} = 17.777$ min, 94% ee).

(R)-3-(4-methoxyphenyl)-5-vinyl-4,5-dihydroisoxazole (4f)




white solid, mp 77.4 – 77.8 °C, 20.1 mg, 99% yield, $[\alpha]_D^{25} -166.0$ (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, $J = 8.8$ Hz, 2H), 6.90 (d, $J = 8.8$ Hz, 2H), 5.99 – 5.91 (m, 1H), 5.38 (d, $J = 17.2$ Hz, 1H), 5.24 (d, $J = 10.4$ Hz, 1H), 5.14 – 5.08 (m, 1H), 3.82 (s, 3H), 3.45 (dd, $J = 16.4, 10.4$ Hz, 1H), 3.08 (dd, $J = 16.4, 8.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 161.06, 155.95, 136.25, 128.20, 122.14, 117.80, 114.13, 81.78, 55.35, 40.79. HRMS (ESI): Exact Mass Calcd. for C₁₂H₁₄NO₂ (M+H)⁺: 204.1019, Found: 204.1022. HPLC (Chiralpak OD–H column, *n*-hexane/*i*-PrOH = 95/5, flow rate = 1.0 mL/min, retention time: $t_{\text{minor}} = 19.754$ min, $t_{\text{major}} = 22.778$ min, 94% ee).

(R)-3-([1,1'-biphenyl]-4-yl)-5-vinyl-4,5-dihydroisoxazole (4g)




white solid, mp 130.1 – 130.9 °C, 22.7 mg, 91% yield, $[\alpha]_D^{25}$ –158.0 (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, J = 8.4 Hz, 2H), 7.63 – 7.59 (m, 4H), 7.44 (t, J = 7.6 Hz, 2H), 7.38 – 7.34 (m, 1H), 6.01 – 5.93 (m, 1H), 5.41 (d, J = 16.8 Hz, 1H), 5.26 (d, J = 10.4 Hz, 1H), 5.20 – 5.13 (m, 1H), 3.51 (dd, J = 16.4, 10.8 Hz, 1H), 3.14 (dd, J = 16.4, 8.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 156.13, 142.81, 140.17, 136.10, 128.92, 128.44, 127.83, 127.37, 127.15, 127.06, 118.00, 82.12, 40.55. HRMS (ESI): Exact Mass Calcd. for C₁₇H₁₆NO (M+H)⁺: 250.1226, Found: 250.1230. HPLC (Chiralpak IC column, *n*-hexane/*i*-PrOH = 90/10, flow rate = 1.0 mL/min, retention time: t_{major} = 19.111 min, t_{minor} = 25.833 min, 91% ee).

(R)-3-(3-(trifluoromethyl)phenyl)-5-vinyl-4,5-dihydroisoxazole (4h)




white solid, mp 71.8 – 72.6 °C, 23.1 mg, 96% yield, $[\alpha]_D^{25}$ –148.0 (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.89 – 7.87 (m, 2H), 7.66 (d, J = 7.6 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 6.01 – 5.93 (m, 1H), 5.43 (d, J = 17.2 Hz, 1H), 5.29 (d, J = 10.4 Hz, 1H), 5.25 – 5.19 (m, 1H), 3.52 (dd, J = 16.4, 10.8 Hz, 1H), 3.15 (dd, J = 16.4, 8.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 155.30, 135.70, 131.45, 131.12, 130.49, 129.71, 129.29, 126.59, 126.55, 123.45, 123.41, 123.38, 118.28, 82.51, 40.17. HRMS (ESI): Exact Mass Calcd. for C₁₂H₁₁F₃NO (M+H)⁺: 242.0787, Found: 242.0792. HPLC (Chiralpak IC column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: t_{major} = 10.586 min, t_{minor} = 12.380 min, 86% ee).

(R)-3-(3-chlorophenyl)-5-vinyl-4,5-dihydroisoxazole (4i)




white solid, mp 69.6 – 71.1 °C, 19.7 mg, 95% yield, $[\alpha]_D^{25}$ –183.0 (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J = 1.6 Hz, 1H), 7.56 – 7.54 (m, 1H), 7.39 – 7.31 (m, 2H), 6.00 – 5.91 (m, 1H), 5.41 (d, J = 17.2 Hz, 1H), 5.28 (d, J = 10.0 Hz, 1H), 5.21 – 5.15 (m, 1H), 3.47 (dd, J = 16.4, 10.8 Hz, 1H), 3.09 (dd, J = 16.4, 8.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 155.34, 135.79, 134.76, 131.35, 130.03, 129.99, 126.71, 124.72, 118.19, 82.35, 40.24. HRMS (ESI): Exact Mass Calcd. for C₁₁H₁₁ClNO (M+H)⁺: 208.0524, Found: 208.0527. HPLC (Chiralpak OD–H column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: t_{major} = 12.181 min, t_{minor} = 13.877 min, 89% ee).

(R)-3-(*m*-tolyl)-5-vinyl-4,5-dihydroisoxazole (4j)




colorless oil, 18.5 mg, 99% yield, $[\alpha]_D^{26} -131.7$ (c 0.6, CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.51 (s, 1H), 7.44 (d, $J = 7.6$ Hz, 1H), 7.31 – 7.21 (m, 2H), 6.01 – 5.92 (m, 1H), 5.40 (d, $J = 17.2$ Hz, 1H), 5.26 (d, $J = 10.4$ Hz, 1H), 5.18 – 5.12 (m, 1H), 3.49 (dd, $J = 16.4, 10.4$ Hz, 1H), 3.12 (dd, $J = 16.4, 8.4$ Hz, 1H), 2.38 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 156.47, 138.43, 136.16, 130.88, 129.46, 128.59, 127.25, 123.87, 117.85, 81.94, 40.60, 21.34. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{12}\text{H}_{14}\text{NO}$ ($\text{M}+\text{H}$) $^+$: 188.1070, Found: 188.1073. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: $t_{\text{minor}} = 19.703$ min, $t_{\text{major}} = 21.050$ min, 95% ee).

(R)-3-(3-methoxyphenyl)-5-vinyl-4,5-dihydroisoxazole (4k)




colorless oil, 17.5 mg, 86% yield, $[\alpha]_D^{26} -155.4$ (c 0.65, CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.31 – 7.26 (m, 2H), 7.17 (d, $J = 7.6$ Hz, 1H), 6.96 (dd, $J = 8.4, 1.6$ Hz, 1H), 6.01 – 5.92 (m, 1H), 5.41 (d, $J = 17.2$ Hz, 1H), 5.27 (d, $J = 10.0$ Hz, 1H), 5.19 – 5.13 (m, 1H), 3.84 (s, 3H), 3.49 (dd, $J = 16.4, 10.8$ Hz, 1H), 3.11 (dd, $J = 16.4, 8.4$ Hz, 1H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 159.72, 156.36, 136.06, 130.82, 129.71, 119.36, 117.98, 116.47, 111.25, 82.11, 55.37, 40.58. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{12}\text{H}_{14}\text{NO}_2$ ($\text{M}+\text{H}$) $^+$: 204.1019, Found: 204.1021. HPLC (Chiralpak AD-H column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 17.718$ min, $t_{\text{minor}} = 19.856$ min, 91% ee).

(R)-3-(naphthalen-2-yl)-5-vinyl-4,5-dihydroisoxazole (4l)




white solid, mp 93.3 – 95.1 °C, 19.6 mg, 88% yield, $[\alpha]_D^{26} -161.0$ (c 1.0, CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.98 – 7.95 (m, 1H), 7.88 – 7.82 (m, 4H), 7.51 – 7.49 (m, 2H), 6.03 – 5.95 (m, 1H), 5.43 (d, $J = 16.8$ Hz, 1H), 5.28 (d, $J = 10.0$ Hz, 1H), 5.23 – 5.17 (m, 1H), 3.60 (dd, $J = 16.4, 10.8$ Hz, 1H), 3.24 (dd, $J = 16.4, 8.4$ Hz, 1H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 156.54, 136.11, 134.04, 133.00, 128.55, 128.36, 127.86, 127.18, 127.12, 126.88, 126.69, 123.58, 118.04, 82.24, 40.49. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{15}\text{H}_{14}\text{NO}$ ($\text{M}+\text{H}$) $^+$: 224.1070, Found: 224.1072. HPLC (Chiralpak AD-H column, *n*-hexane/*i*-PrOH = 95/5, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 14.438$ min, $t_{\text{minor}} = 16.774$ min, 91% ee).

***tert*-butyl (*R*)-3-(5-vinyl-4,5-dihydroisoxazol-3-yl)-1*H*-indole-1-carboxylate (**4m**)**




white solid, mp 95.1 – 95.9 °C, 23.7 mg, 76% yield, $[\alpha]_D^{26} -86.0$ (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 8.25 – 8.23 (m, 1H), 8.11 (d, $J = 8.4$ Hz, 1H), 7.70 (s, 1H), 7.40 – 7.30 (m, 2H), 6.01 – 5.93 (m, 1H), 5.42 (d, $J = 16.8$ Hz, 1H), 5.27 (d, $J = 10.0$ Hz, 1H), 5.15 – 5.08 (m, 1H), 3.52 (dd, $J = 16.0, 10.4$ Hz, 1H), 3.15 (dd, $J = 16.0, 8.4$ Hz, 1H), 1.69 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 151.82, 149.37, 136.11, 135.69, 127.11, 126.55, 125.50, 123.76, 123.10, 117.95, 115.00, 111.89, 84.70, 80.84, 41.47, 28.17. HRMS (ESI): Exact Mass Calcd. for C₁₈H₂₁N₂O₃ (M+H)⁺: 313.1547, Found: 313.1549. HPLC (Chiralpak AD–H column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 14.169$ min, $t_{\text{minor}} = 16.564$ min, 85% ee).

(*R*)-3-(thiophen-2-yl)-5-vinyl-4,5-dihydroisoxazole (4n**)**



colorless oil, 16.1 mg, 90% yield, $[\alpha]_D^{26} -129.3$ (c 0.75, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.38 – 7.37 (m, 1H), 7.18 (d, $J = 2.8$ Hz, 1H), 7.05 (dd, $J = 4.0, 4.8$ Hz, 1H), 5.99 – 5.90 (m, 1H), 5.39 (d, $J = 17.2$ Hz, 1H), 5.26 (d, $J = 10.0$ Hz, 1H), 5.14 (q, $J = 8.4$ Hz, 1H), 3.49 (dd, $J = 16.4, 10.8$ Hz, 1H), 3.12 (dd, $J = 16.4, 8.4$ Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 152.13, 135.78, 132.07, 128.28, 128.25, 127.28, 118.18, 82.24, 41.32. HRMS (ESI): Exact Mass Calcd. for C₉H₁₀NOS (M+H)⁺: 180.0478, Found: 180.0481. HPLC (Chiralpak AD–H column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 13.642$ min, $t_{\text{minor}} = 15.135$ min, 95% ee).


(*R*)-3-phenyl-6-vinyl-5,6-dihydro-4*H*-1,2-oxazine (4o**)**



colorless oil, 18.1 mg, 97% yield, $[\alpha]_D^{26} -237.7$ (c 0.85, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.69 – 7.66 (m, 2H), 7.37 – 7.35 (m, 3H), 5.97 – 5.89 (m, 1H), 5.41 (d, $J = 17.6$ Hz, 1H), 5.27 (d, $J = 10.4$ Hz, 1H), 4.35 – 4.30 (m, 1H), 2.69 – 2.58 (m, 2H), 2.18 – 2.11 (m, 1H), 1.96 – 1.86 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 154.27, 135.89, 129.45, 128.45, 125.33, 117.72, 75.35, 24.09, 21.08. HRMS (ESI): Exact Mass Calcd. for

C₁₂H₁₄NO (M+H)⁺: 188.1070, Found: 188.1073. HPLC (Chiralpak IG column, *n*-hexane/*i*-PrOH = 92/8, flow rate = 1.0 mL/min, retention time: *t*_{major} = 15.152 min, *t*_{minor} = 16.377 min, 90% ee).


(*R*)-3-phenyl-7-vinyl-4,5,6,7-tetrahydro-1,2-oxazepine (**4p**)



colorless oil, 18.7 mg, 93% yield, [α]_D²⁶ -57.0 (c 1.0, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, *J* = 6.4 Hz, 2H), 7.44 – 7.39 (m, 3H), 6.05 – 5.97 (m, 1H), 5.36 (d, *J* = 17.6 Hz, 1H), 5.19 (d, *J* = 10.4 Hz, 1H), 4.24 – 4.20 (m, 1H), 3.23 – 3.16 (m, 1H), 2.81 – 2.77 (m, 1H), 2.09 – 1.97 (m, 2H), 1.94 – 1.84 (m, 1H), 1.63 – 1.57 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 175.72, 138.07, 135.44, 130.35, 128.58, 126.92, 115.34, 80.30, 35.39, 29.44, 21.86. HRMS (ESI): Exact Mass Calcd. for C₁₃H₁₆NO (M+H)⁺: 202.1226, Found: 202.1230. HPLC (Chiralpak OD–H column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: *t*_{minor} = 12.350 min, *t*_{major} = 18.285 min, 94% ee).

5. Synthetic transformation of products


5.1 Olefin metathesis of compound **4d**



Under argon atmosphere, a solution of compound **4d** (50.4 mg, 0.2 mmol) and but-3-en-1-ylbenzene (79.2 mg, 0.6 mmol, 3.0 equiv.) in dry DCM (2 mL) was treated with Grubbs 2nd catalyst (5.1 mg, 3 mol %). The reaction mixture was refluxed for 24 h. After cooling to room temperature, DCM was evaporated under reduced pressure and the residue was purified by flash column chromatography on silica gel (PE/EtOAc = 19/1) to afford product **5** (61.2 mg).

(*R,E*)-3-(4-bromophenyl)-5-(4-phenylbut-1-en-1-yl)-4,5-dihydroisoxazole (**5**). white solid, mp 67.7 – 68.8 °C, 86% yield, [α]_D²³ -83.0 (c 1.0, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.52 (s, 4H), 7.29 – 7.25 (m, 3H), 7.20 – 7.15 (m, 2H), 5.90 – 5.83 (m, 1H), 5.59 (dd, *J* = 15.2, 7.6 Hz, 1H), 5.11 (dd, *J* = 18.0, 8.8 Hz, 1H), 3.39 (dd, *J* = 16.4, 10.4 Hz, 1H), 2.99 (dd, *J* = 16.4, 8.8 Hz, 1H), 2.72 (t, *J* = 7.2 Hz, 2H), 2.43 – 2.39 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 155.70, 141.40, 134.64, 131.93, 128.69, 128.45, 128.41, 128.36, 128.08, 125.96, 124.24, 82.41, 40.37, 35.24, 33.91. HRMS (ESI): Exact Mass Calcd. for C₁₉H₁₉BrNO (M+H)⁺: 356.0645, Found: 356.0646. HPLC (Chiralpak OD–H column, *n*-hexane/*i*-PrOH = 99/1, flow rate = 1.0 mL/min, retention time: *t*_{major} = 37.630 min, *t*_{minor} = 44.594 min, 89% ee).

5.2 Epoxidation of compound **2a**




To a solution of compound **2a** (49.0 mg, 0.15 mmol) in CH_2Cl_2 (2 mL), $m\text{-CPBA}$ (70%, 147.9 mg, 0.6 mmol, 4.0 equiv.) was added at 0 °C. The reaction mixture was stirred for 24 h at room temperature. Upon completion of the reaction (monitored by TLC), the reaction was quenched with saturated aqueous Na_2SO_3 . The organic phase was separated, washed with saturated aqueous NaHCO_3 , brine, dried over anhydrous Na_2SO_4 , and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel using petroleum ether/EtOAc (9/1) to afford the product **6** (85% yield, 3:2 dr).

major **6**, white solid, mp 136.5 – 138.6 °C, 26.2 mg, 51% yield, $[\alpha]_D^{27} +6.0$ (c 0.5, CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.78 (d, $J = 8.4$ Hz, 2H), 7.65 (d, $J = 8.0$ Hz, 2H), 7.41 – 7.37 (m, 3H), 7.27 (d, $J = 8.0$ Hz, 2H), 3.76 – 3.70 (m, 1H), 3.43 – 3.40 (m, 1H), 3.19 – 3.05 (m, 2H), 2.99 (t, $J = 4.4$ Hz, 1H), 2.79 (dd, $J = 4.4, 2.4$ Hz, 1H), 2.37 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 157.85, 144.55, 132.07, 130.78, 130.49, 129.65, 128.67, 128.62, 126.97, 63.17, 53.32, 47.71, 36.54, 21.60. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_3\text{S}$ ($\text{M}+\text{H}$) $^+$: 343.1111, Found: 343.1117. HPLC (Chiralpak IG column, $n\text{-hexane}/i\text{-PrOH} = 70/30$, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 37.774$ min, $t_{\text{minor}} = 41.754$ min, 96% ee).

minor **6**, white solid, mp 88.4 – 90.1 °C, 17.4 mg, 34% yield, $[\alpha]_D^{27} +2.0$ (c 0.5, CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.81 (d, $J = 8.4$ Hz, 2H), 7.65 (d, $J = 6.8$ Hz, 2H), 7.42 – 7.36 (m, 3H), 7.28 (d, $J = 8.0$ Hz, 2H), 4.28 – 4.22 (m, 1H), 3.47 (dd, $J = 6.4, 4.0$ Hz, 1H), 3.03 (d, $J = 10.0$ Hz, 2H), 2.97 – 2.95 (m, 1H), 2.91 (t, $J = 4.4$ Hz, 1H), 2.39 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 157.97, 144.48, 132.17, 130.78, 130.46, 129.62, 128.65, 128.01, 126.97, 60.66, 52.35, 44.80, 35.47, 21.60. HRMS (ESI): Exact Mass Calcd. for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_3\text{S}$ ($\text{M}+\text{H}$) $^+$: 343.1111, Found: 343.1117. HPLC (Chiralpak IG column, $n\text{-hexane}/i\text{-PrOH} = 60/40$, flow rate = 1.0 mL/min, retention time: $t_{\text{major}} = 25.022$ min, $t_{\text{minor}} = 35.241$ min, 96% ee).

5.3 Synthesis of β -amino alcohol **7** and 6-vinyl-1,3-oxazinan-2-one (**8**)



Under argon atmosphere, compound **4a** (34.6 mg, 0.2 mmol) was dissolved in dry Et₂O (8.0 mL). Lithium aluminium hydride (22.8 mg, 0.6 mmol, 3.0 equiv.) was added to the above solution. The reaction mixture was refluxed for 36 h. After cooling to room temperature, the reaction was quenched with aqueous NH₄Cl (20 mL), and then extracted with CH₂Cl₂ (10 mL×3). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated. The crude product was purified by flash column chromatography on silica gel using petroleum ether/EtOAc (7:1) to afford the product **7** (8:1 dr).

(3R,5S)-5-amino-5-phenylpent-1-en-3-ol (7). white solid, mp 295.3 – 297.1 °C, 22.7 mg, 64% yield, [α]_D²⁶ –135.4 (c 0.33, CH₂Cl₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.48 – 7.30 (m, 5H), 6.62 (br s, 2H), 5.83 – 5.75 (m, 1H), 5.13 – 5.08 (m, 1H), 4.98 – 4.95 (m, 1H), 4.23 (dd, *J* = 8.0, 6.4 Hz, 1H), 3.76 – 3.71 (m, 1H), 3.34 (br s, 1H), 1.93 – 1.77 (m, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 142.43, 140.87, 129.01, 128.44, 127.73, 113.79, 68.93, 53.45, 43.09. HRMS (ESI): Exact Mass Calcd. for C₁₁H₁₆NO (M+H)⁺: 178.1226, Found: 178.1230. HPLC (Chiralpak OD–H column, *n*-hexane/*i*-PrOH = 85/15, flow rate = 1.0 mL/min, retention time: *t*_{minor} = 11.600 min, *t*_{major} = 13.077 min, 94% ee).


An oven-dried Schlenk tube (25 mL) equipped with a magnetic stir bar was charged with compound **7** (17.7 mg, 0.1 mmol) in anhydrous THF (2 mL), followed by the addition of 1,1'-carbonyldiimidazole (CDI) (32.4 mg, 0.2 mmol). The reaction was refluxed for 6 h under argon. Upon completion of the reaction (monitored by TLC), the solvent was removed under reduced pressure. The residue was dissolved in EtOAc, and washed with sat. aqueous NH₄Cl and brine. The organic phase was dried over anhydrous Na₂SO₄, concentrated and purified by flash column chromatography on silica gel (petroleum ether/EtOAc = 1:1) to afford the product **8** (92% yield, 7:1 dr). The (4*S*,6*R*)-**8** was obtained in 76% yield by recrystallization from dichloromethane.

(4S,6R)-4-phenyl-6-vinyl-1,3-oxazinan-2-one (8). White solid, 76% yield. ¹H NMR (400 MHz, CDCl₃) δ 7.42 – 7.33 (m, 5H), 5.95 – 5.86 (m, 1H), 5.44 (d, *J* = 17.2 Hz, 1H), 5.35 (br s, 1H), 5.28 (d, *J* = 10.8 Hz, 1H), 4.91 – 4.87 (m, 1H), 4.64 (dd, *J* = 11.6, 4.4, 1H), 2.27 – 2.22 (m, 1H), 1.89 – 1.80 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 153.68, 140.51, 134.83, 129.20, 128.74, 126.09, 117.68, 77.32, 55.59, 36.91. HRMS (ESI): Exact Mass Calcd. for C₁₂H₁₄NO₂ (M+H)⁺: 204.1019, Found: 204.1021.

Table 1. Crystal data and structure refinement for compound 8.

Identification code	hufang-hxp_0302_auto
Empirical formula	C ₁₂ H ₁₃ NO ₂
Formula weight	203.23
Temperature/K	274.64(16)
Crystal system	monoclinic
Space group	P2 ₁ /n
a/Å	9.2864(3)
b/Å	10.8028(3)
c/Å	11.5140(4)
α/°	90
β/°	109.190(4)
γ/°	90
Volume/Å ³	1090.89(6)
Z	4
ρ _{calc} /cm ³	1.237
μ/mm ⁻¹	0.685
F(000)	432.0
Crystal size/mm ³	0.15 × 0.12 × 0.08
Radiation	Cu Kα (λ = 1.54184)
2θ range for data collection/°	11.546 to 153.276
Index ranges	-11 ≤ h ≤ 11, -13 ≤ k ≤ 11, -14 ≤ l ≤ 14
Reflections collected	6938
Independent reflections	2192 [R _{int} = 0.0386, R _{sigma} = 0.0363]
Data/restraints/parameters	2192/1/136
Goodness-of-fit on F ²	1.091
Final R indexes [I ≥ 2σ (I)]	R ₁ = 0.0666, wR ₂ = 0.1928
Final R indexes [all data]	R ₁ = 0.0747, wR ₂ = 0.2035
Largest diff. peak/hole / e Å ⁻³	0.42/-0.28

6. Scale-up synthesis of compound 2a



A flame dried Schlenk tube was cooled to room temperature and filled with argon. To this flask were added [Ir(COD)Cl]₂ (0.04 mmol, 4 mol %), phosphoramidite ligand **L**₂ (0.08 mmol, 8 mol %), *n*-propylamine (1.0


mL) and THF (1.0 mL). The reaction mixture was heated at 50 °C for 0.5 h and the volatile solvent was removed *in vacuo* to afford a pale-yellow solid. Then, K₂CO₃ (0.5 mmol, 0.5 equiv.), a solution of **1a** (1.0 mmol) in CH₂Cl₂ (20 mL) were added and the reaction mixture was stirred for 48 h. Upon completion of the reaction (monitored by TLC), the reaction mixture was filtrated with celite and washed with CH₂Cl₂. The solvent was removed under reduced pressure and the residue was purified by flash column chromatography on silica gel to afford the product **2a** (93% yield, 93% ee).

7. References


- [1] Guo, Y.-Q.; Zhao, M.-N.; Ren, Z.-H.; Guan, Z.-H. *Org. Lett.* **2018**, *20*, 3337–3340.
- [2] Wang, L.; Li, P.; Menche, D. *Angew. Chem. Int. Ed.* **2010**, *49*, 9270–9273.
- [3] Wang, L.; Zhang, K.; Wang, Y.; Li, W.; Chen, M.; Zhang, J. *Angew. Chem. Int. Ed.* **2020**, *59*, 4421–4427.

8. NMR spectra of compounds 2a–2s, 4a–4p and 5–8


^1H NMR spectrum of compound 2a (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound 2a (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2b** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2b** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **2c** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **2c** (CDCl₃, 100 MHz)




^1H NMR spectrum of compound **2d** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2d** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2e** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2e** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **2f** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **2f** (CDCl₃, 100 MHz)




^1H NMR spectrum of compound **2g** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2g** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2h** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2h** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2i** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2i** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2j** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2j** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2k** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2k** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **21** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **21** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2m** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2m** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2n** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2n** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2o** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2o** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2p** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2p** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2q** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2q** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **2r** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **2r** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **2s** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **2s** (CDCl₃, 100 MHz)




^1H NMR spectrum of compound **4a** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4a** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **4b** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4b** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **4c** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4c** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **4d** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4d** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **4e** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4e** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **4f** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4f** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **4g** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4g** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **4h** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4h** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **4i** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4i** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **4j** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **4j** (CDCl₃, 100 MHz)




¹H NMR spectrum of compound **4k** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **4k** (CDCl₃, 100 MHz)




^1H NMR spectrum of compound **41** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **41** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **4m** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **4m** (CDCl₃, 100 MHz)




^1H NMR spectrum of compound **4n** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4n** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **4o** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4o** (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **4p** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **4p** (CDCl_3 , 100 MHz)




¹H NMR spectrum of compound **5** (CDCl₃, 400 MHz)




¹³C NMR spectrum of compound **5** (CDCl₃, 100 MHz)




^1H NMR spectrum of compound **6** (major) (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **6** (major) (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **6** (minor) (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **6** (minor) (CDCl_3 , 100 MHz)




^1H NMR spectrum of compound **7** (DMSO- d_6 , 400 MHz)




^{13}C NMR spectrum of compound **7** (DMSO- d_6 , 100 MHz)




^1H NMR spectrum of compound **8** (CDCl_3 , 400 MHz)




^{13}C NMR spectrum of compound **8** (CDCl_3 , 100 MHz)




9. HPLC spectra for compounds 2a–2s, 4a–4p and 5–6




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	26.967	1.60612e4	299.27985	49.9391
2	PDA 254 nm	34.066	1.61004e4	234.97787	50.0609




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	26.642	4.72158e4	868.20557	97.9137
2	PDA 254 nm	33.923	1006.04779	15.00314	2.0863




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	23.474	5355.04980	119.09879	50.0918
2	PDA 254 nm	29.812	5335.42188	92.39308	49.9082




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	23.365	2.81806e4	611.02057	98.7030
2	PDA 254 nm	29.963	370.31766	6.33330	1.2970




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	29.413	5405.50049	96.68369	50.4443
2	PDA 254 nm	34.782	5310.28223	80.60548	49.5557




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	27.728	2.29153e4	392.76523	96.4258
2	PDA 254 nm	33.757	849.40820	12.43409	3.5742




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	29.385	4422.99707	74.17055	50.0298
2	PDA 254 nm	34.181	4417.71924	64.60667	49.9702




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	28.883	3.05136e4	512.06750	94.7941
2	PDA 254 nm	33.922	1675.75439	24.77319	5.2059




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254.16 nm	31.202	1.44315e4	233.45490	50.0013
2	PDA 254.16 nm	35.994	1.44307e4	200.96352	49.9987




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254.16 nm	30.452	4.22524e4	673.70184	98.6412
2	PDA 254.16 nm	35.454	582.02930	8.25200	1.3588




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	46.491	6932.46191	74.45089	50.0669
2	PDA 254 nm	65.258	6913.93311	52.52824	49.9331




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	46.998	1.24963e4	130.80913	98.7595
2	PDA 254 nm	66.760	156.96873	1.19828	1.2405




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	48.706	2224.79419	20.70044	50.1387
2	PDA 254 nm	56.662	2212.48779	18.31616	49.8613




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	49.871	1.99476e4	161.25204	97.2849
2	PDA 254 nm	59.985	556.72223	4.10839	2.7151




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	23.290	1.31609e4	275.59933	49.8838
2	PDA 254 nm	29.677	1.32222e4	214.83112	50.1162




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	21.884	2.88562e4	627.56708	98.4812
2	PDA 254 nm	28.315	445.03397	7.46473	1.5188




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	39.135	2.88280e4	412.03534	49.9263
2	PDA 254 nm	42.135	2.89131e4	376.51834	50.0737




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	38.514	2.84698e4	413.26364	97.4970
2	PDA 254 nm	41.838	730.88403	9.93582	2.5030




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	20.119	1.35099e4	345.16788	49.9352
2	PDA 254 nm	24.225	1.35450e4	283.78735	50.0648




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	19.910	1.80977e4	468.50916	98.4584
2	PDA 254 nm	24.079	283.35599	6.34157	1.5416




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	21.289	1.94571e4	485.52396	50.1488
2	PDA 254 nm	26.456	1.93416e4	375.70361	49.8512




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	21.507	1966.74353	48.81145	5.3143
2	PDA 254 nm	26.629	3.50416e4	653.60272	94.6857




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	33.395	1.63527e4	238.01045	49.9865
2	PDA 254 nm	40.153	1.63616e4	205.29463	50.0135




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	33.806	2.05620e4	293.59781	99.2595
2	PDA 254 nm	40.933	157.57225	2.00664	0.7405




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	22.746	1.67712e4	294.92230	49.6924
2	PDA 254 nm	30.553	1.69788e4	169.03539	50.3076




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	23.247	673.65228	10.97509	1.4463
2	PDA 254 nm	29.962	4.59040e4	447.61475	98.5537




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	20.547	6756.59326	161.55437	49.9021
2	PDA 254 nm	46.059	6783.09131	69.43627	50.0979




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	20.299	9243.96484	224.88922	97.0548
2	PDA 254 nm	45.552	280.51703	2.98567	2.9452




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	29.201	2.46311e4	450.95746	49.9760
2	PDA 254 nm	34.527	2.46548e4	386.06219	50.0240




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	29.916	3.32195e4	583.60968	99.0617
2	PDA 254 nm	35.600	314.63745	4.75592	0.9383




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	26.142	1.35700e4	272.39581	50.2693
2	PDA 254 nm	31.210	1.34246e4	225.19232	49.7307




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	25.521	1.26995e4	257.25595	64.8141
2	PDA 254 nm	30.528	6894.23584	118.05122	35.1859




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	12.223	8919.99414	329.77625	49.8827
2	PDA 254 nm	14.163	8961.94141	295.20792	50.1173




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	12.270	163.08018	5.88615	1.6670
2	PDA 254 nm	14.196	9620.04199	316.98193	98.3330




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	23.398	3.80032e4	874.99371	50.0360
2	PDA 254 nm	27.191	3.79485e4	712.33801	49.9640




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	23.508	515.29761	11.50023	2.1125
2	PDA 254 nm	27.270	2.38773e4	462.84125	97.8875




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	15.518	2.32929e4	769.38062	49.8565
2	PDA 254 nm	24.034	2.34271e4	483.71106	50.1435




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	15.596	1096.22339	34.38272	4.1008
2	PDA 254 nm	24.030	2.56357e4	530.39777	95.8992




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	27.820	2.74864e4	714.84052	49.9697
2	PDA 254 nm	30.075	2.75197e4	653.80774	50.0303




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	28.121	3.69333e4	914.74957	95.9805
2	PDA 254 nm	30.563	1546.69250	37.05835	4.0195




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	19.173	3.73125e4	1318.24670	50.1081
2	PDA 254 nm	21.969	3.71515e4	1218.15845	49.8919




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	19.721	4.22978e4	1344.04138	87.9115
2	PDA 254 nm	22.818	5816.25781	180.42314	12.0885




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	19.732	4.99934e4	1541.91064	49.9507
2	PDA 254 nm	22.003	5.00921e4	1439.00488	50.0493




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	20.322	6.67856e4	1911.61597	95.3578
2	PDA 254 nm	22.814	3251.25952	94.14796	4.6422




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	22.747	2.01724e4	665.94897	49.8013
2	PDA 254 nm	25.431	2.03334e4	621.40747	50.1987




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	22.617	4.30791e4	1345.97412	96.6043
2	PDA 254 nm	25.395	1514.24365	44.72794	3.3957




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	16.023	2.25727e4	616.26129	49.8096
2	PDA 254 nm	17.861	2.27453e4	583.22217	50.1904




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	15.941	3.79763e4	1050.81470	96.7582
2	PDA 254 nm	17.777	1284.52844	33.05643	3.2418




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	19.289	2.41663e4	671.07513	49.9955
2	PDA 254 nm	22.931	2.41707e4	585.51563	50.0045




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	19.754	977.97791	26.58458	2.9630
2	PDA 254 nm	22.778	3.20280e4	726.07227	97.0370




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	19.172	8072.64502	294.77164	57.7978
2	PDA 254 nm	25.715	5894.39160	175.55519	42.2022




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	19.111	2.88379e4	1082.38330	95.4989
2	PDA 254 nm	25.833	1359.19348	38.61534	4.5011




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254.16 nm	10.841	2.83099e4	1202.91553	49.3771
2	PDA 254.16 nm	12.649	2.90241e4	1159.57361	50.6229




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254.16 nm	10.586	2.80144e4	1135.48071	93.0330
2	PDA 254.16 nm	12.380	2097.93384	88.99281	6.9670




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	12.083	3.99314e4	1626.16687	49.8125
2	PDA 254 nm	13.631	4.02319e4	1510.26746	50.1875




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	12.181	2.79276e4	1108.96167	94.5672
2	PDA 254 nm	13.877	1604.41321	56.15255	5.4328




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	19.061	3.45227e4	1056.47290	49.8475
2	PDA 254 nm	20.412	3.47340e4	1004.29309	50.1525




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	19.703	801.50470	23.7144	2.5779
2	PDA 254 nm	21.050	3.02900e4	844.37195	97.4221




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	17.809	2.04057e4	551.24860	50.0101
2	PDA 254 nm	19.910	2.03975e4	504.31970	49.9899




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	17.718	8.08922e4	2097.40063	95.2545
2	PDA 254 nm	19.856	4065.62109	99.07423	4.7455




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	14.421	4.97738e4	1747.43677	48.7469
2	PDA 254 nm	16.754	5.23329e4	1535.21460	51.2531




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	14.438	7.23118e4	2414.40845	95.6843
2	PDA 254 nm	16.774	3261.49048	99.86243	4.3157




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	13.967	2.85029e4	712.03992	49.8842
2	PDA 254 nm	16.211	2.86352e4	632.05792	50.1158




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	14.169	3.65472e4	845.72095	92.6744
2	PDA 254 nm	16.564	2888.92163	60.38203	7.3256




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	13.422	1.36113e4	450.63660	49.9075
2	PDA 254 nm	14.900	1.36617e4	415.72729	50.0925




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	13.642	3.68070e4	1179.10706	97.6831
2	PDA 254 nm	15.135	873.02716	24.12109	2.3169




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	15.080	2.85420e4	1213.61987	49.6673
2	PDA 254 nm	16.257	2.89244e4	1135.31262	50.3327




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	15.152	2.70595e4	1190.66467	94.7531
2	PDA 254 nm	16.377	1498.40527	59.29599	5.2469




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	12.587	1.61958e4	516.27911	49.8943
2	PDA 254 nm	18.191	1.62644e4	457.71677	50.1057




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254. nm	12.350	1461.34460	48.88551	2.8608
2	PDA 254 nm	18.285	4.96206e4	1156.93945	97.1392




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	39.046	2.32221e4	262.10471	50.6208
2	PDA 254 nm	44.282	2.26525e4	233.82022	49.3792




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	37.630	3.66823e4	386.96817	94.6748
2	PDA 254 nm	44.594	2063.28394	21.97522	5.3252




Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 280.16 nm	38.353	9200.17578	117.25249	50.2860
2	PDA 280.16 nm	42.154	9095.52148	111.29817	49.7140



Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 280.16 nm	37.774	1.77595e4	228.48381	97.8749
2	PDA 280.16 nm	41.754	385.60281	4.72605	2.1251



Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 280.16 nm	24.902	7120.41455	134.75426	50.1862
2	PDA 280.16 nm	34.897	7067.57031	95.82932	49.8138



Peak	Processed channel	Retention time (min)	Peak area (mAU*s)	Peak height (mAU)	Peak area (%)
1	PDA 254 nm	25.022	1.81723e4	343.74432	97.9537
2	PDA 254 nm	35.241	379.63364	5.14803	2.0463